UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines
Category: #health  By Pankaj Singh  Date: 2020-07-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines

Even though the COVID-19 vaccine hasn’t been launched worldwide, it seems that leading nations are competing over who will have first access once a vaccine is ready. Recently, the government of the UK has reportedly signed an agreement with Pfizer Inc. and BioNTech SE, leading pharmaceutical companies developing a vaccine against COVID-19, to supply 30 million doses of m-RNA based vaccine candidates being developed under BNT162 program.

Sources cite that the company’s experimental vaccine candidates are currently in development and are subject to regulatory approval. The terms and conditions of the deal were based on the volume of doses and timing of delivery.

For the record, the BNT162 program leverages BioNTech’s mRNA technology and is supported by Pfizer’s vaccine development and manufacturing capabilities. The vaccine candidates are currently undergoing clinical trials and not presently authorized for distribution across the world. Both companies are using pre-clinical and clinical data to decide the future course of vaccine development.

Also, both companies are currently evaluating the minimum four potential vaccines, each of which represents a unique combination of mRNA format and target antigen. BioNTech and Pfizer previously announced the preliminary outcomes from BNT162b1, the most advanced mRNA formulations.

The data showed that BNT162b1 can produce neutralizing antibodies in humans at or above the levels detected in the plasma from COVID-19 recovered patients at relatively low dose levels.

Both companies are planning to commence Phase 2b/3 efficiency and safety trials later this month. If studies are successful, Pfizer and BioNTech will seek Conditional Marketing Authorization and regulatory review until October 2020. Both companies aim to produce up to 100 mn doses by 2020 and over 1.3 bn doses by the end of 2021.

For the record, SARC-COV-2 has infected over 14 million and took the lives of 0.8 million people across the globe, and the effective vaccine seems to be the only way that can put an end on the pandemic.

Source - https://www.businesswire.com/news/home/20200719005057/en/Pfizer-BioNTech-Announce-Agreement-United-Kingdom-30



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...

Australia retail industry in disarray with major slump in sales
Australia retail industry in disarray with major slump in sales
By Pankaj Singh

Australia’s retailers are reportedly facing a huge crisis of sorts, with the latest data depicting a massive fall in sales volumes. As the nation’s second-largest state enforces a lockdown to fight the ongo...